Clinical trials: Light Chain Deposition Disease, active
Monoclonal Gammopathy of Renal Significance
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
- Trial name
- NCT06418477
- Testing
- Dara-CyBorD
- Where
- 3 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Multiple Myeloma, Amyloidosis
Registry for Adults With Plasma Cell Disorders (PCD's)
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric…
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT03717844
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Light Chain Deposition Disease, Smoldering Multiple Myeloma
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
This randomized phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering) multiple myeloma.
- Trial name
- NCT01169337
- Testing
- Clinical Observation, Lenalidomide, Quality-of-Life Assessment
- Where
- 605 sites in United States, Ireland and 1 more
- Volunteers
- 226 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Amyloidosis
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study.
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT05283993
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital